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a b s t r a c t
INTRODUCTION: Birt–Hogg–Dubé syndrome (BHDS) is a rare autosomal dominant disease. It is caused
by constitutional mutations in the FLCN gene. Since BHDS is a rare syndrome therefore it is unknown to
many physicians. However, it is important to identify this rare syndrome at early stages because incidence
of renal cancer in BHD patients is very high and its detection at early stages can prevent its metastasis.
Hence, we want to present a case of BHDS and draw the attention of the treating physician to this rare
inherited disorder and discuss its appropriate diagnosis and management.
CASE PRESENTATION: We present a case of a 50-year old male presented to the consulting clinics of
a University Hospital with right ﬂank pain since the last 2 months. The Computed Tomography (CT)
and biopsy on the right renal mass indicated clear cell type renal cell carcinoma with signiﬁcant lymphadenopathy. Past history of cystic lung disease and pneumothorax along with positive ﬁnding of renal
cell carcinoma on CT and biopsy suggested Birt-Hogg-Dubı́e (BHD) syndrome. The patient underwent
right radical nephrectomy and lymph node dissection. His 3 months post- surgery follow up CT scan
indicated disease recurrence.
CONCLUSION: In conclusion, it is important to identify this rare syndrome at early stages. Diagnosis for
the patients with a positive family history for renal cell cancer and pneumothorax should be considered.
FLCN sequencing should also be taken into account in patients and their families because incidence of
renal cancer in BHD patients is very high and detection at early stages can prevent its metastasis.
© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Birt–Hogg–Dubé syndrome (BHDS), which is also known as
Hornstein–Knickenberg syndrome, is a rare autosomal dominant
disease originally reported in 1977. [1] BHDS is an autosomal dominant monogenic disorder caused by constitutional mutations in the
FLCN gene [2–4]. FLCN is a tumor suppressor gene [5–7], and codes
for the protein folliculin [8]. Since the ﬁrst discovery of the mutation in the FLCN gene, various FLCN germ line mutations have been
identiﬁed in Caucasian and Asian families [9–11]. The clinical manifestations of this syndrome are as follows; Lung cyst that is the hall
mark of lung involvement that increases the risk of pneumothorax
[12,13]. Secondly manifestations of the skin are; ﬁbrofolliculomas,
trichodiscomas, and acrochordons, which mainly occurs on the
face, neck, and upper trunk [1,14]. However, the utmost severe
manifestation of the syndrome is the susceptibility to renal cell carcinoma (RCC) [15]. More than 600 families with BDHS have been
reported till 2016 [16]. Since BHDS is a rare syndrome therefore it is
unknown to many physicians. More families with BHDS may exist
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and the syndrome is likely to be under-diagnosed. Since it is a rare
disease its diagnosis and management is a crucial element. Therefore we present a case of BHDS and hope to draw the attention of
the treating physician to this rare inherited disorder.
2. Case
A 50-year old male presented to the consulting clinics of a
University Hospital with right ﬂank pain since the last 2 months.
Family history showed that the mother had bullous lung disease.
Moreover about 10 years back the patient presented with complain of shortness of breath and was diagnosed with cystic lung
disease and underwent video assisted thoracoscopy (VAT)/apical
pleurectomy/pleurodosis. On examination his vitals were stable
and systematic examination was unremarkable except there was
decrease air entry in middle and lower zone bilaterally. His laboratory test showed anemia and raised C reactive protein. The
Computed Tomography (CT) presented ill-deﬁned inﬁltrating right
infrahilar and lower pole renal lesion with a partly exophytic component along with multiple enlarged adjacent centrally located
necrotic lymph nodes in the aortocaval and retrocaval locations
(Fig. 1) and enlarged mediastinal lymph nodes. Moreover emphysematous changes in the lungs with patchy ﬁbrotic changes and
scattered nodularity was found representing sequel of old infection
with typical cyst in the lungs bilaterally. A biopsy was per-
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Fig. 1. The CT scan shows a suspicious looking ill-deﬁned inﬁltrating right infrahilar and lower pole renal lesion with a partly exophytic component. Multiple enlarged
adjacent centrally necrotic lymph nodes in the aortocaval and retrocaval locations.

formed on the right renal mass that indicated clear cell type renal
cell carcinoma with signiﬁcant lymphadenopathy. Histopathology
showed multiple cores comprising of ﬁbro collagenous tissue inﬁltrated by neoplastic lesion comprising of polygonal cells showing
clear to eosinophilic cytoplasm and round to oval hyperchromatic nuclei. Focally, papillary like structure was noted. The lesion
was surrounded by lymphocytic population. However, no deﬁnite
lymphoid was observed. Special PAS stain highlighted abundant
intracytoplasmic glycogen in the neoplastic cells. The CT and biopsy
ﬁndings of renal cell carcinoma in combination with the past history of cystic lung disease and pneumothorax and a positive family
history of bullous lung disease suggested Birt-Hogg-Dubı́e (BHD)
syndrome. The patient underwent right radical nephrectomy and
lymph node dissection which was performed by the urologist. On
discharge the patient was referred for chest physiotherapy as he
had low lung compliance. Standard of care was given according to
institutional policies and intervention according to EAU guideline
Two months post- surgery the patient again presented with cough
and chest X- ray revealed right pneumothorax. He was admitted
for chest tube insertion and was treated for lower respiratory tract
infection. His follow up CT three months following radical nephrectomy indicated disease recurrence (Fig. 2). He is being referred for
consideration of systemic treatment.
The work has been reported in line with the SCARE criteria [17].

Fig. 2. The CT scan reveals interval follows radical nephrectomy and lymphodectomy and increase in caval node at renal hilum on right side measuring 29 mm in
short axis. A simple renal cortical cyst evident at the lower pole of the left kidney.

3. Discussion
BHDS is a rare hereditary syndrome with a higher increased risk
of, multiple lung cysts predisposing to recurrent pneumothorax,
increased risk of renal cancer and ﬁbro-folliculomas in the skin.
Multiple lung cysts are seen in approximately 67–90% of patients
with BHDS and about 40% experience pneumothorax [12]. This
was evident in our case where the patient ﬁrst presented with
an apical bleb and developed cystic lung disease and pneumothorax. The treatment of pneumothorax in BHDS is similar to the
treatment of pneumothorax of other etiologies [18]. Almoosa et al.
suggested [19] that chemical and surgical pleurodesis decreases the
pneumothorax recurrence rate, therefore pleurodesis after the ﬁrst
spontaneous pneumothorax in BHDS has been suggested. Further,
thorascopic pleural covering technique has also been suggested
as a way of preventing recurrence of pneumothorax in patients
with BHDS [20]. In our case the patient underwent Video Assisted
Thoracoscopy (VAT)/Apical Pleurectomy/Pleurodosis when he was
diagnosed with cystic ﬁbrosis and pneumothorax for the ﬁrst time.
Renal Cell Carcinoma (RCC) is one of the most dreaded complication of BHDS and its diagnosis and management is very crucial.
Approximately 30% of BHDS patients develop renal tumors, and it is
commonly found in middle-aged patients with mean age 50.7. [21]
Early diagnosis of BHDS is important so that patients are included
in RCC screening programs. It would help in preventing metastatic
disease, which has miserable prognosis. Since the syndrome is rare,
the diagnosis is often delayed for years and the variable presentation of the syndrome contributes to the diagnostic difﬁculties.
Along with the diagnostic difﬁculties, management is also a crucial
element of RCC. It is recommended that if any tumor is greater than
3 cms a partial nephrectomy should be performed with an effort to
clear kidney of all grossly evident tumors. Tumor <3 cms diameter can be observed because the risk of metastasis appears to be
relatively low in this situation [22]. The patients presenting with
small renal tumors (<4 cm) may undergo radiofrequency ablation
(RFA) or cryoablation. However, nephrectomy is the recommended
standard treatment procedure [23]. In our case study the patient
underwent radical nephrectomy and lymph node dissection upon
diagnosis of renal cell carcinoma with a tumor size of 9*4*4 cms
and lymphadenopathy.
Skin manifestations are also common in BHDS and are seen in
approximately 58–90% of patients [21]. The involvement of the skin
is benign, and no follow up is needed [24].
Recently, the European BHDS consortium has proposed a set of
criteria for the diagnosis of BHDS (Table 1) [25]
Therefore it is essential that upon diagnosis of BHDS, the patients
should undergo examination of the skin for ﬁbro-folliculomas, CT
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Table 1
Diagnostic Criteria for BHDS as proposed by the European BHDS consortium.
• A patient has Birt-Hogg-Dube syndrome if:
 The patient has a pathogenic FLCN mutation, or
 The patient has >4 ﬁbrofolliculomas or trichodiscomas, at least one histologically conﬁrmed, of adult onset, or
• If 2 of the 3 following manifestations are present:
• Multiple bilateral lung cysts with basal predominance and no other apparent cause. With or without spontaneous pneumothorax.
• A ﬁrst degree relative with BHDS
• Early debut (<50 years) of renal tumors or the presence of:
 Multiple bilateral renal tumors
 Renal tumors of the chromophobe/oncocytotic type

imaging of the thorax for lung cysts, abdominal MR or CT imaging
for renal tumors as well as genetic screening for pathogenic FLCN
mutations. In our case we did not test for FLNC mutation. Identiﬁcation of FLCN defects in families with BHD has led to new insights
in the penetrance and clinical variability of this syndrome. It is proposed that diagnostic criteria for BHDS should be based on clinical
manifestations and the outcome of DNA testing. And it is important
that all patients suspected of having BHD should be offered genetic
testing to conﬁrm the diagnosis [26]. Infact, if a pathogenic FLCN
mutation is identiﬁed, all at-risk relatives should be offered genetic
counseling and predictive testing [24].
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4. Strengths
Through our case report we hope to draw the attention of the
treating physician to this rare inherited disorder which has deleterious outcomes. Early diagnosis of BHDS is important so that
patients are included in RCC screening programs. It would help
in preventing metastatic disease, which has miserable prognosis.
Since the syndrome is rare, the diagnosis is often delayed for years
and the variable presentation of the syndrome contributes to the
diagnostic and management difﬁculties.

5. Weakness
The weakness of our study was that we were not able to evaluate
the FLNC mutation in our patients. It is observed that the offspring
of an individual with BHDS have a 50% chance of inheriting the
pathogenic variant. Therefore, prenatal diagnosis for pregnancies,
at increased risk is possible if the FLCN pathogenic variant of an
affected family member has been identiﬁed.

6. Conclusion
In conclusion, it is important to identify this rare syndrome
at early stages. Diagnosis and management for the patients with
a positive family history for renal cell cancer and pneumothorax
should be considered. FLCN sequencing should also be considered
in patients and their families because incidence of renal cancer in
BHD patients is very high and detection at early stages can prevent
its metastasis.

7. Learning points
1. BHD is a rare disease causing renal cell carcinoma
2. Usual histology is chromophobe tumor, however our patient histology was clear cell type.
3. Aggressive nature of the disease with lack of adjuvant treatment
and morbidity related to pulmonary and renal issues have been
addressed in this report.

Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy
of the written consent is available for review by the Editor-in-Chief
of this journal on request”.
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